JAK2 JH2 Fluorescence Polarization Assay and Crystal Structures for Complexes with Three Small Molecules

ACS Medicinal Chemistry Letters

Volumn 8, Issue 6, 2017, Pages 614-617

  Newton, Ana S ^a   Deiana, Luca ^a   Puleo, David E ^b   Cisneros, José A ^a   Cutrona, Kara J ^a   Schlessinger, Joseph ^b   Jorgensen, William L ^a  

^a YALE UNIVERSITY   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Filgotinib (GLPG0634); Fluorescence polarization; FP; JAK2; JAK2 JH2; Janus Kinase 2; JNJ7706621; NVP BSK805; Protein crystallography; Pseudokinase domain

Indexed keywords

FILGOTINIB; JANUS KINASE 2; JANUS KINASE INHIBITOR; JNJ 7706621; NVP BSK 805; UNCLASSIFIED DRUG;

ALLOSTERIC SITE; ARTICLE; BINDING AFFINITY; COMPLEX FORMATION; CRYSTAL STRUCTURE; DRUG SYNTHESIS; FLUORESCENCE POLARIZATION; PRIORITY JOURNAL;

EID: 85020403925     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/acsmedchemlett.7b00154     Document Type: Article

References (22)

1. Shuai, K.; Liu, B. Regulation of JAK-STAT signaling in the immune system Nat. Rev. Immunol. 2003, 3, 900-911 10.1038/nri1226
2. Saharinen, P.; Silvennoinen, O. The pseudokinase domain is required for suppression of basal activity of JAK2 and JAK3 tyrosine kinases and for cytokine-inducible activation of signal transduction J. Biol. Chem. 2002, 277, 47954-47963 10.1074/jbc.M205156200
3. Saharinen, P.; Vihinen, M.; Silvennoinen, I. Autoinhibition of JAK2 tyrosine kinase is dependent on specific regions in its pseudokinase domain Mol. Biol. Cell 2003, 14, 1448-1459 10.1091/mbc.E02-06-0342
4. Sanz, A. S.; Niranjan, Y.; Hammaren, H.; Ungureanu, D.; Ruijtenbeek, R.; Touw, I. P.; Silvennoinen, O.; Hilhorst, R. The JH2 domain and SH2-JH2 linker regulate JAK2 activity: A detailed kinetic analysis of wild type and V617F mutant kinase domains Biochim. Biophys. Acta, Proteins Proteomics 2014, 1844, 1835-1841 10.1016/j.bbapap.2014.07.003
5. Silvennoinen, O.; Ungureanu, D.; Niranjan, Y.; Hammaren, H.; Bandaranayake, R.; Hubbard, S. R. New insights into the structure and function of the pseudokinase domain in JAK2 Biochem. Soc. Trans. 2013, 41, 1002-1007 10.1042/BST20130005
6. Baxter, E. J.; Scott, L. M.; Campbell, P. J.; East, C.; Fourouclas, N.; Swanton, S.; Vassiliou, G. S.; Bench, A. J.; Boyd, E. M.; Curtin, N.; Scott, M. A.; Erber, W. N.; Green, A. R. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders Lancet 2005, 365, 1054-1061 10.1016/S0140-6736(05)74230-6
7. Levine, R. L.; Wadleigh, M.; Cools, J.; Ebert, B. L.; Wernig, G.; Huntly, B. J. P.; Boggon, T. J.; Wlodarska, L.; Clark, J. J.; Moore, S.; Adelsperger, J.; Koo, S.; Lee, J. C.; Gabriel, S.; Mercher, T.; D'Andrea, A.; Frohling, S.; Dohner, K.; Marynen, P.; Vandenberghe, P.; Mesa, R. A.; Tefferi, A.; Griffein, J. D.; Eck, M. J.; Sellers, W. R.; Meyerson, M.; Golub, T. R.; Lee, S. J.; Gilliland, D. G. Cancer Cell 2005, 7, 387-397 10.1016/j.ccr.2005.03.023
8. James, C.; Ugo, V.; Le Couedic, J. P.; Staerk, J.; Delhommeau, F.; Lacout, C.; Garcon, L.; Raslova, H.; Berger, R.; Bennaceur-Griscelli, A.; Villeval, J. L.; Constantinescu, S. N.; Casadevall, N.; Vainchenker, W. A unique clonal JAK2 mutation leading to constitutive signaling causes polycythaemia vera Nature 2005, 434, 1144-1148 10.1038/nature03546
9. Kralovics, R.; Passamonti, F.; Buser, A. S. A gain-of-function mutation of JAK2 in myeloproliferative disorders N. Engl. J. Med. 2005, 352, 1779-1790 10.1056/NEJMoa051113
10. Zhao, R. X.; Xing, S.; Li, Z.; Fu, X. Q.; Li, Q. S.; Krantz, S. B.; Zhao, Z. H. J. Identification of an acquires JAK2 mutation in Polycythemia vera J. Biol. Chem. 2005, 280, 22788-22792 10.1074/jbc.C500138200
11. Hammaren, H. M.; Ungureanu, D.; Grisouard, J.; Skoda, R. C.; Hubbard, S. R.; Silvennoinen, O. ATP binding to the pseudokinase domain of JAK2 is critical for pathogenic activation Proc. Natl. Acad. Sci. U. S. A. 2015, 112, 4642-4647 10.1073/pnas.1423201112
12. Haan, C.; Behrmann, I.; Haan, S. Perspectives for the use of structural information and chemical genetics to develop inhibitors of Janus Kinases J. Cell. Mol. Med. 2010, 14, 504-527 10.1111/j.1582-4934.2010.01018.x
13. Dolgin, E. Companies hope for kinase inhibitor JAKpot Nat. Rev. Drug Discovery 2011, 10, 717-718 10.1038/nrd3571
14. Changelian, P. S.; Flanagan, M. E.; Ball, D. J.; Kent, C. R.; Magnuson, K. S.; Martin, W. H.; Rizzuti, B. J.; Sawyer, P. S. Prevention of organ allograft rejection by a specific Janus Kinase 3 inhibitor Science 2003, 302, 875-878 10.1126/science.1087061
15. Yang, S. M.; Malaviya, R.; Wilson, L. J.; Argentieri, R.; Chen, X.; Yang, C. M.; Wang, B. B.; Cavender, D.; Murray, W. V. Simplified staurosporine analogs as potent JAK3 inhibitors Bioorg. Med. Chem. Lett. 2007, 17, 326-331 10.1016/j.bmcl.2006.10.062
16. Li, Z.; Xing, S.; Wang, S. F.; Ho, W. T.; Zhao, Z. Z. J. Autoinhibition of JAK2 tyrosine kinase is dependent on specific regions in its pseudokinase domain Exp. Hematol. 2007, 35, 1624-1632 10.1016/j.exphem.2007.07.003
17. Chen, J. J.; Thakur, K. D.; Clark, M. P.; Laughlin, S. K.; George, K. M.; Bookland, R. G.; Davis, J. R.; Cabrera, E. J.; Easwaran, V.; De, B.; Zhang, Y. G. Development of pyrimidine-based inhibitors of Janus tyrosine kinase 3 Bioorg. Med. Chem. Lett. 2006, 16, 5633-5638 10.1016/j.bmcl.2006.08.022
18. Lea, W. A.; Simeonov, A. Fluorescence polarization assays in small molecule screening Expert Opin. Drug Discovery 2011, 6, 17-32 10.1517/17460441.2011.537322
19. Lin, R. H.; Connolly, P. J.; Huang, S. L.; Wetter, S. K.; Lu, Y. H.; Murray, W. V.; Emanuel, S. L.; Gruninger, R. H.; Fuentes-Pesquera, A. R.; Rugg, C. A.; Middleton, S. A.; Jolliffe, L. K. 1-acyl-1H-[1,2,4]triazole-3,5-diamine analogues as novel and potent anticancer cyclin-dependent kinase inhibitors: Synthesis and evaluation of biological activities J. Med. Chem. 2005, 48, 4208-4211 10.1021/jm050267e
20. Baffert, F.; Régnier, C. H.; De Pover, A.; Pissot-Soldermann, C.; Tavares, G. A.; Blasco, F.; Brueggen, J.; Chène, P.; Drueckes, P.; Erdmann, D.; Furet, P.; Gerspacher, M.; Lang, M.; Ledieu, D.; Nolan, L.; Ruetz, S.; Trappe, J.; Vangrevelinghe, E.; Wartmann, M.; Wyder, L.; Hofmann, F.; Radimerski, T. Potent and selective inhibitor of polycythemia by the quinoxaline JAK2 inhibitor NVP-BSK805 Mol. Cancer Ther. 2010, 9, 1945-1955 10.1158/1535-7163.MCT-10-0053
21. Menet, C. J.; Fletcher, S. R.; Van Lommen, G.; Geney, R.; Blanc, J.; Smits, K.; Jouannigot, N.; Deprez, P.; van der Aar, E. M.; Clement-Lacroix, P.; Lepescheux, L.; Galien, R.; Vayssiere, B.; Nelles, L.; Christophe, T.; Brys, R.; Uhring, M.; Ciesielki, F.; Van Rompaey, L. Triazolopyridines as selective JAK1 inhibitors: From hit identification to GLPG0634 J. Med. Chem. 2014, 57, 9323-9342 10.1021/jm501262q
22. Puleo, D. E.; Kucera, K.; Hammarén, H.; Ungureanu, D.; Newton, A. S.; Silvennoinen, O.; Jorgensen, W. L.; Schlessinger, J. Identification and Characterization of JAK2 Pseudokinase Domain Small Molecule Binders. ACS Med. Chem. Lett. 2017, 10.1021/acsmedchemlett.7b00153